Literature DB >> 7069575

The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.

K M Giacomini, S E Swezey, K Turner-Tamiyasu, T F Blaschke.   

Abstract

Disopyramide exhibits saturable binding to plasma proteins in the therapeutic plasma concentration range. Because of this property, controversy exists in the literature regarding the pharmacokinetic properties of the drug. The purposes of this study were to reassess the pharmacokinetic properties of disopyramide in humans, taking into consideration both total and unbound concentrations and to use disopyramide as a model compound to study the effect of drug binding on the renal clearance of both total and unbound drug. A single intravenous dose of disopyramide (1.5 mg/kg) was administered to eight normal volunteers. Blood and urine samples were collected for 36 h. Total concentrations of disopyramide in plasma and urine were determined by high pressure liquid chromatography. Binding of disopyramide to plasma proteins was determined by equilibrium dialysis. In all subjects the binding of disopyramide to plasma proteins was saturable, but there were considerable differences in binding between subjects. The volume of distribution, total body clearance, and renal clearances of both total and unbound drug were calculated. Because only the total body clearance and renal clearance of unbound compound are not dependent upon unbound fraction (alpha), these are the only parameters which can be reported without qualification as to the concentration. The mean +/-DS total body clearance of unbound drug in the eight subjects was 5.40 +/- 2.80 ml/min/kg. About 50% of this was due to renal elimination. A statistically significant negative correlation of the renal clearance of total disopyramide with time was observed in seven of eight subjects, whereas a significant correlation between the renal clearance of unbound disopyramide and time was observed in only one subject. This suggests that the renal clearance of unbound disopyramide is independent of alpha, while the renal clearance of total disopyramide is dependent upon alpha.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7069575     DOI: 10.1007/bf01059180

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  20 in total

1.  The pharmacokinetics of Norpace.

Authors:  A Karim
Journal:  Angiology       Date:  1975-01       Impact factor: 3.619

2.  The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.

Authors:  J W Ward; G R Kinghorn
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

3.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

4.  Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.

Authors:  A Karim; C Kook; R L Novotney; J Zagarella; J Campion
Journal:  Drug Metab Dispos       Date:  1978 May-Jun       Impact factor: 3.922

5.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

6.  Effect of saturable binding on the pharmacokinetics of drugs: a simulation.

Authors:  S Oie; T W Guentert; T N Tozer
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

7.  The renal clearance of disopyramide after bolus intravenous injection.

Authors:  J R Lawrence; S M Bryson; D J Sumner; B C Campbell; B Whiting
Journal:  Biopharm Drug Dispos       Date:  1979 Oct-Dec       Impact factor: 1.627

8.  Assay of disopyramide in plasma by high-pressure liquid chromatography.

Authors:  K F Ilett; L P Hackett; L J Dusci; R Tjokrosetio
Journal:  J Chromatogr       Date:  1978-07-21

9.  Effect of plasma protein binding on renal clearance of drugs.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

10.  Haemodynamic and electrocardiographic effects of intravenous disopyramide (rythmodan) following acute myocardial infarction.

Authors:  G J Davies; P K Marrott; J R Muir
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

View more
  19 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Stereoselective drug disposition: potential for misinterpretation of drug disposition data.

Authors:  A M Evans; R L Nation; L N Sansom; F Bochner; A A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

3.  Bioavailability of disopyramide in normal volunteers using unbound concentration.

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework.

Authors:  W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

5.  Effect of ethanol intake on disopyramide elimination by healthy volunteers.

Authors:  H Olsen; J E Bredesen; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

7.  Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.

Authors:  K M Giacomini; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 9.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 10.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.